Consistent with this, clinical data support the alteration of NAD+ and PAR metabolism in psoriasis, pointing to NAMPT, PARP1, and AIFM1 as novel therapeutic targets to treat skin inflammatory disorders. This evidence concerns the gene PARP1 and psoriasis.